Industry experts speaking within a newly released WuXi Xpress White Paper on RNA have identified 2019 as potentially a key turning point for the modality, sparking the beginnings of a new era for RNA therapeutics.
RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as validation in drug discovery programmes, respectively.
This article discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era.
Messenger RNA (mRNA) - the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell's DNA into the proteins essential for maintaining cell function and ensuring an organism’s survival, will revolutionise the biopharmaceutical industry.
A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are now starting to emerge for the application of vector-based ddRNAi.
Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel tumour dependencies and molecular targets.
RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics wave, and in combination with the human genome-sequencing projects, would constitute the holy grail of modern genetics.
Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs.
In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'.
Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate and improve the quality of functional genomics based drug discovery by enabling a much more targeted approach that effectively integrates the discovery and validation of novel targets.
One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets in underserved disease areas.
RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice for target validation in cell culture systems.
Purified RNA is crucial for use in a range of downstream applications performed by life scientists, most notably reverse transcription PCR (RT-PCR), quantitative real-time PCR (qPCR) and cDNA synthesis.
In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market analyses are presented in detail in a recently published MicroRNA 2008 market report.